The combination of BRAF and MEK inhibitor has been demonstrated to be more effective than a single agent BRAF inhibitor even though no direct studies have been conducted to identify which combination would be more adequate for V600K melanoma patients [27,28,29]. This evidence concerns the gene MAP2K7 and melanoma.